Expert ConsensusClinical Guidelines & Best PracticesDiagnosis & AssessmentTreatment: PharmacologicalClinical RelevanceDOI
4 min read
Jump to:

Patient-friendly summary

If you read nothing else

This Saudi national guideline tells doctors to assess low back pain and sciatica with a quick risk questionnaire, avoid routine scans, and use medications and procedures carefully because the evidence that they help is limited.

Bottom line

A rigorously developed national guideline recommending clinical-assessment-led care with restricted imaging and cautious, individualised treatment, though most recommendations rest on low-certainty evidence.

Moderate evidence

Published

2026
0 years ago
Current

Evidence hierarchy

Meta-analysis
Systematic Review
RCT
Cohort
Case-Control
Case Report
Expert Opinion ◀ this study

Study participants

Not applicable (guideline; no new patient cohort recruited)16 years and olderNot reported

Adults aged 16 years and older with non-specific low back pain or sciatica in Saudi Arabia

Full research — for clinicians and curious readers

Study Summary

This is a national clinical practice guideline developed by a multidisciplinary Saudi Task Force to standardise the assessment and management of non-specific low back pain (LBP) and sciatica in adults aged 16 and older. Using the GRADE-ADOLOPMENT methodology and adapting NICE guideline NG59 (plus one added question on pain neuroscience education), the Task Force addressed 11 clinical questions and updated the supporting literature through searches in PubMed, Embase and the Cochrane Library (2016–2022). It issued strong recommendations for using validated risk-assessment tools (e.g., the STarT Back Screening Tool) and for stratified management, and conditional recommendations covering imaging, pharmacological treatment for sciatica, psychological interventions, multidisciplinary return-to-work programmes, epidural injections, image-concordant pathology, spinal decompression, radiofrequency denervation and pain neuroscience education, with certainty of evidence ranging from very low to moderate. The overarching message is that care should be guided by clinical assessment, with restricted imaging, careful drug selection, and appropriate use of psychological, multidisciplinary and procedural interventions.

70/100
Evidence StrengthModerate
Study Quality
Sample Size
Replication

Key Findings

Validated risk-assessment tools are strongly recommended after clinical examinationHigh

The Task Force gave a strong recommendation (very low certainty of evidence) to use validated risk-assessment tools such as the STarT Back Screening Tool at the first encounter, judging the net clinical benefit clear despite weak evidence. These tools are meant to support, not replace, clinical decision-making.

Stratified management guided by risk tools is strongly recommendedHigh

A strong recommendation with moderate certainty supports using validated tools (e.g., STarT Back) to stratify management by risk of chronicity and disability. Evidence showed little to no difference for most outcomes versus usual care, but one trial reported improved SF-12 physical component scores at 4 months, and cost-utility analyses favoured stratified care.

Imaging should be restricted and is not recommended for routine useHigh

The Task Force made no recommendation for or against imaging (X-ray or MRI) to improve pain, function or psychological distress (conditional, low certainty). Imaging is advised only when red flags are present or when results would change management, since degenerative findings are common in asymptomatic people and imaging increases costs and healthcare utilisation.

Pharmacological treatment for sciatica is only conditionally suggested with no clear first-line agentHigh

Conditional recommendation (very low certainty). Across NSAIDs, benzodiazepines, gabapentinoids and oral corticosteroids versus placebo, none showed clear benefit; most produced little to no difference in pain or function and increased adverse events. Benzodiazepines were worse than placebo for responder-defined pain relief. Non-pharmacological options should form the basis of management.

Psychological, multidisciplinary return-to-work, and procedural interventions are conditionally suggestedMedium

Conditional recommendations were made for psychological interventions (low certainty, to be used within a package including exercise +/- manual therapy), multidisciplinary return-to-work programmes (low certainty), epidural injections for sciatica (very low certainty), image-concordant pathology to predict surgical response (low certainty), spinal decompression, radiofrequency denervation, and pain neuroscience education.

Study Methodology
Study Design
National clinical practice guideline developed via GRADE-ADOLOPMENT, adapting NICE guideline NG59, with GRADE certainty rating and Evidence-to-Decision consensus voting (60% threshold)
Sample Size
11 clinical questions; underlying evidence base included observational studies and RCTs identified in NICE NG59 plus update searches (2016-2022) — no patient cohort was recruited by the guideline itself
Duration
Guideline development spanned 2021-2023 (literature searches Apr-May 2022; recommendation meetings Dec 2022-May 2023); published Jan 2026
Population
Adults aged 16 years and older with non-specific low back pain or sciatica in primary, secondary or tertiary care in Saudi Arabia; excludes serious spinal pathology, inflammatory back pain, progressive neurological deficit and suspected cauda equina syndrome
Outcome Measures
GRADE certainty of evidence (high/moderate/low/very low) · Recommendation strength (strong vs conditional) · Pain (VAS, NRS) · Function (RMDQ, ODI) · Quality of life (SF-12, SF-36, EQ-5D) · Psychological distress (HADS, BDI) · Discrimination/calibration of risk tools (AUC, sensitivity, specificity, R-squared) · Return-to-work rates · Healthcare utilisation and cost-effectiveness

Strengths

  • Used the internationally recognised GRADE-ADOLOPMENT methodology and adapted the high-quality NICE NG59 guideline, with AGREE II appraisal of source guidelines
  • Developed by a broad multidisciplinary Task Force (rheumatology, orthopaedic/spine surgery, physiotherapy, rehabilitation, anaesthesiology) trained in guideline methodology, with international methodological support
  • Transparent processes including duplicate independent screening and data extraction, GRADE certainty rating, structured Evidence-to-Decision frameworks, consensus voting, external peer review and formal national endorsement
  • Recommendations explicitly contextualised to Saudi Arabia's healthcare system, costs, equity and feasibility, with literature updated through 2022

Limitations

  • The certainty of the underlying evidence was low to very low for most recommendations, with only one based on moderate certainty, limiting confidence in the estimated effects
  • It is a guideline/consensus document rather than primary research; it generated no new patient data and relies heavily on the evidence base assembled for NICE NG59
  • The guideline applies to non-specific LBP and sciatica only and explicitly excludes serious spinal pathology, inflammatory back pain, progressive neurological deficit and cauda equina syndrome
  • Much of the cited Saudi epidemiological context comes from cross-sectional, self-reported studies, limiting causal inference and generalisability
  • Several contextual judgements (values, equity, feasibility) relied on Task Force experience rather than direct evidence

Key Takeaways for Patients

What This Means for You

  1. 01If you have low back pain or sciatica, your clinician may use a short questionnaire (such as the STarT Back Screening Tool) at your first visit to gauge your risk of long-term problems and tailor your care.
  2. 02Routine X-rays or MRI scans are usually not needed and are reserved for warning signs (red flags) or when the result would change your treatment, because scans often show age-related changes that are also seen in people without pain.
  3. 03For sciatica, no single medication is clearly best, and the guideline emphasises non-drug approaches; any medication should be chosen carefully because benefits are often small and side effects are common.
  4. 04Psychological support, exercise-based and multidisciplinary return-to-work programmes, and in selected cases epidural injections or surgery may help, but the strength of the evidence is limited and care should be individualised.

Read the Full Paper

Access the complete peer-reviewed study from Journal of Clinical Medicine

View Full Study

Related Research

●●●●● LandmarkNarrative Review

Myofascial Pain Syndrome: An Update on Clinical Characteristics, Etiopathogenesis, Diagnosis, and Treatment

Steen et al.·Muscle & Nerve·2025

This comprehensive narrative review synthesizes current evidence on myofascial pain syndrome, finding sufficient support only for local anesthetic injections while highlighting that many common treatments lack adequate evidence.

Clinical Guidelines & Best PracticesRead →
●●●●● LandmarkNarrative Review

Pharmacologic treatment of fibromyalgia: an update

Yang Li et al.·Frontiers in Pharmacology·2025

A 2025 narrative review concluding that current fibromyalgia drugs help only a minority of patients and should be used as part of an individualized, multimodal plan alongside exercise, education, and psychological support.

PharmacologicalRead →
●●●●● LandmarkNarrative Review

Myofascial pain – A major player in musculoskeletal pain

Lam et al.·Best Practice & Research Clinical Rheumatology·2024

Comprehensive review of myofascial pain syndrome, affecting 20-95% of musculoskeletal pain patients. Emphasizes multimodal treatment approaches and need for early recognition.

Clinical Guidelines & Best PracticesRead →
●●●●● LandmarkNarrative Review

Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review

Valeria Giorgi et al.·Current Pain and Headache Reports·2024

A practice-based narrative review of the drugs used to treat fibromyalgia, concluding that current pharmacological options offer limited benefit and are best applied within a personalized, multidisciplinary approach.

PharmacologicalRead →